Novo Nordisk appoints Stephen Gough as senior principal clinical scientist

Danish insulin giant Novo Nordisk (NOV: N) has appointed Stephen Gough as senior principal clinical scientist.

Professor Gough will be responsible for providing clinical guidance on developing new molecules and drugs from an early stage through to Phase III and beyond to treat diabetes and obesity. He joins from the Oxford Centre for Diabetes Endocrinology and Metabolism, where he led active diabetes research groups focusing on autoimmunity.

Alan Moses, chief medical officer of Novo Nordisk, said: “Novo Nordisk can only stay at the forefront of research and development in diabetes and obesity through the recruitment of exceptional scientists and clinicians. With his key clinical expertise, his experience as a researcher focused on patient issues, and his compassion for patients with diabetes, Professor Gough will have a vital role in working toward Novo Nordisk’s ambition of Changing Diabetes.”